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Heat shock proteins (HSPs) are molecular chaperones that bind tumor antigens and medi-
ate their uptake into antigen presenting cells. HSP–antigen complexes are then directed
toward either the MHC class I pathway through antigen cross presentation or the conven-
tional class II pathway, leading to activation of T cell subsets. Uptake of HSP-chaperoned
polypeptides can involve both receptor-mediated and receptor-independent routes, and
mechanisms of antigen sorting between the Class I and II pathways after uptake are
currently under investigation. The processes involved in internalization of HSP–antigen
complexes differ somewhat from the mechanisms previously determined for (unchaper-
oned) particulate and free soluble antigens. A number of studies show that HSP-facilitated
antigen cross presentation requires uptake of the complexes by scavenger receptors (SR)
followed by processing in the proteasome, and loading onto MHC class I molecules. In this
review we have examined the roles of HSPs and SR in antigen uptake, sorting, processing,
cell signaling, and activation of innate and adaptive immunity.
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INTRODUCTION
Heat shock proteins (HSPs) are a class of polypeptides powerfully
induced by heat shock that mediate profound levels of stress resis-
tance (Craig, 1985; Ellis, 2007). HSPs are molecular chaperones,
binding to (holding) and refolding other cellular polypeptides
(clients) with aberrant conformations (Ellis, 2007). There are a
number of families of molecular chaperone families (a–d), with
members of class a (Hsp70, Hsp110, GRP170) and class c (Hsp90,
Grp94/Gp96) thought to be of particular signiﬁcance in tumor
immunology (Murshid et al., 2011c). (Grp is the abbreviation
for glucose regulated protein and such proteins are retained in the
endoplasmic reticulum, ER.) The molecular chaperone activity of
class a and class c chaperones appears to be conferred by two func-
tional domains: a dedicated peptide binding domain that seizes
client polypeptides and an ATPase domain (Scheibel et al., 1998;
Mayer and Bukau, 2005; Vogel et al., 2006). HSPs are allosteric
molecules, one domain reciprocally affecting the other, and when
polypeptide moieties bind to the peptide binding domain, ATP is
hydrolyzed to ADP and orthophosphate and when ATP binds,
associated peptides are discarded. These properties have been
intensely studied for Hsp70 and Hsp90 and are largely inferred
for the sibling proteins. The ability to hold polypeptide clients
appears to correlate with the size of class a chaperones, the smaller
class a member (Hsp70) binding to smaller peptides with medium
afﬁnity while larger class a chaperones (Hsp110 and Grp170),with
very large peptide binding domains, bind tightly to their clients,
including peptides and whole proteins (Oh et al., 1999; Park et al.,
2006).
Heat shock protein–peptide complexes (HSP.PC) can be used
as vaccines to elicit antigen-speciﬁc cytotoxic lymphocytes (CTL)
responses (Srivastava, 2000; Manjili et al., 2002; Wang et al., 2003;
Enomoto et al., 2006; Gong et al., 2010). In order for polypep-
tides bound to HSPs to activate adaptive immunity, associated
antigens must be internalized by antigen presenting cells (APC)
and inserted into the antigen presentation pathways. Indeed,HSPs
have been shown to be taken up by dendritic cells (DC), the most
efﬁcient professional APC (Steinman et al., 1983; Heath and Car-
bone, 2009). Antigen presentation occurs through a number of
pathways. Intracellular proteins were shown to be processed by
digestion through the multiple protease activities in the protea-
some and antigens presented on the cell surface by major his-
tocompatibility class I (MHCI) molecules found in all cells and
thus displayed to CD8+ T cells to permit immunosurveillance
(Neefjes and Momburg, 1993). By contrast, exogenous antigens
after internalization into immune cells are processed in lysosomes
and presented on the cell surface by major histocompatibility class
II (MHCII) molecules restricted to cells of the immune system
(Cresswell, 1994). It was subsequently shown that another anti-
gen presentation pathway exists permitting external antigens to
enter the MHC class I pathway (Norbury et al., 2002, 2004). This
process, antigen cross presentation permits external antigens to be
presented by APC in the context of MHC class I and activate
CD8+ CTL to kill virus infected or malignant cells (Norbury
et al., 2002, 2004; Figure 1). Antigen cross presentation was
shown to be a complex process requiring external antigens to
enter cells, penetrate sites for protein processing, and associate
with MHC class I molecules in intracellular vesicular structures
although many aspects of this process are incompletely under-
stood. We aim to elucidate some of the mechanisms by which
antigens bound to HSP interact with APC and mediate antigen
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FIGURE 1 | Antigen presentation pathways for HSP-bound polypeptides.
HSP.PCs bind to surface receptors on DC including SRECI and LOX-1 and are
internalized in complexes with the receptors. Binding to these receptors may
also trigger secondary activation of Toll-like receptors (TLR2 or TLR4) that may
amplify antigen cross presentation. Alternatively some studies suggest direct
binding of HSPs toTLR. HSP binding to cell surface SRA/CD204 is inhibitory
to TLR4 activity and likely antagonizes the immune responses induced by
HSPs through LOX-1 or SRECI. HSP.PC are internalized by SRECI or LOX-1
into endosomes with the subsequent release of the peptides from the
HSP.PC complex. Such peptides are then processed either within endosomes
or undergo trafﬁcking to the cytosol where they encounter the proteasomal
system. Processed peptides are then loaded either onto MHC class I in the
ER or phagosomes or onto MHC class II molecules in lysosomes and
presented to, respectively CD8+T cells and CD4+T cells. The triage
mechanisms directing HSP-chaperoned peptides toward either of these two
pathways are currently not known.
cross presentation as compared with the pathways utilized for
unchaperoned antigens.
HSPs IN TUMOR IMMUNITY AND ANTI-CANCER VACCINES:
COMMON AND UNCOMMON ANTIGENS
When HSPs are extracted from cancer cells under controlled con-
ditions and introduced into tumor bearing hosts they can induce
immunity to the parent tumor cells (Srivastava, 2002;Manjili et al.,
2003; Wang et al., 2003, 2010; Murshid et al., 2011c). The major
paradigm for using tumor derived HSP as vaccines involves their
assumed ability to bind to antigenic oligopeptides (Srivastava,
2002; Murshid et al., 2011c). This hypothesis takes into account
the chaperone properties of the HSPs mentioned above and their
relative abundance inside cells and is supported by a considerable
body of data. However some controversy remains, particularly for
the ER resident class c chaperone Grp94 (Gp96; Chandawarkar
et al., 1999,2004; Jockheck-Clark et al., 2010).Although some indi-
rect studies suggested that Grp94 could bind to antigenic peptides
in vitro, these ﬁndings have been disputed (Ying and Flatmark,
2006). In addition, this protein has been shown to initiate tumor
rejection in the absence of bound peptides, presumably through
stimulation of innate immunity (Nicchitta, 2003). However these
drawbacks may not apply to the other class a and c chaperones.
Hsp70has for instance been shown to bind to oligopeptides in vitro
by phage display and afﬁnity chromatography approaches and
in vivo by mass spectrometry (Flynn et al., 1989; Fourie et al.,
1994; Gragerov and Gottesman, 1994; Grossmann et al., 2004).
Heat shock protein levels are elevated in many tumor types due
to the increased requirement for molecular chaperones needed to
stabilize the abundant mutant and over-expressed oncoproteins
found in cancer (Calderwood et al., 2006; Calderwood and Gong,
2011). The expansion of molecular chaperone clients during stress
was shown previously to trigger expression of HSPs due to ele-
vated transcription and selective translation (Calderwood et al.,
2010). HSP–oncoprotein complexes thus accumulate in abundant
levels in such tumor cells in response to the increased folding bur-
den and can be used to prepare chaperone-based vaccines: this
is the major rationale behind using HSPs in tumor immunother-
apy (Srivastava and Old, 1988; Kamal et al., 2003; Murshid et al.,
2011c). The multiple mutations found in cancer genomes appear
to be required to overcome the matrix of regulatory barriers to
transformation and progression that characterize normal cells
(Vogelstein and Kinzler, 1993; Hanahan and Weinberg, 2000).
Alterations such as mutation and overexpression occur in growth
factor receptors and downstream signaling pathways and permit
cytokine-independent growth in cancer. In addition, mutations
in tumor suppressor genes override their inhibitory effects of
their gene products on cancer (Hanahan and Weinberg, 2000).
However not all mutations are equal. Many cells in the tumor
population may be unable to initiate efﬁcient tumor formation
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and tumorigenesis appears to be maintained by driver mutations
in minority clones of tumor-initiating cells (TIC; Carter et al.,
2009; Hanahan and Weinberg, 2011). Thus many of the random
mutations accumulating in the large non-TIC population may
have passenger status and are unlikely to select for malignancy.
A high proportion of the antigenic epitopes in individual cancers
could therefore be unique andnot sharedwith other tumors.How-
ever, many tumors express common antigens (such as HER2-neu
andMUC1 in breast cancer) or re-express embryonic and develop-
mental genes such as Mart1 and gp100 common to many cancers
(Engelhard et al., 2002). For tumor immunotherapy in patients,
Grp94 and Hsp70 vaccines have been used in an autologous mode,
with the patients receiving HSP complexes derived from their own
primary tumors for immunotherapy (Srivastava and Old, 1988).
This approach was based on experimental studies of chemically
induced rodent cancers, in which Grp74 and Hsp70 vaccines were
shown to be effective only in an autologous context and were not
cross reactive even with tumors from matched animals bearing
tumors induced by the same carcinogen (Udono and Srivastava,
1993; Chandawarkar et al., 2004).
Characterizing the antigenic peptide repertoires associatedwith
individual HSPs extracted from tumor cells has however rarely
been attempted. Thus although it is suspected that the individual
class a and class c HSPs chaperone a wide spectrum of potential
antigenic epitopes that may be representative of the cell proteome
and that individual HSPs may favor distinct subpopulations of
such peptides, these issues have not been comprehensively studied
and the question remains open.
PATHWAYS OF ANTIGEN CROSS PRESENTATION: SOLUBLE,
PARTICULATE, AND HSP–CHAPERONED ANTIGENS
Antigen presenting cells utilize at least two pathways for sampling
external antigens and displaying them to T lymphocytes. These
are the MHC class I and MHC class II pathways. However, the
mechanisms used for sorting and trafﬁcking of antigens between
the MHC class I or class II pathways varies according to the physi-
cal nature of the antigen (Inaba and Inaba, 2005). Particulate and
soluble antigens are dealt with quite differently.
(a) Particulate antigens are taken up by phagocytosis and enter
vesicular structures known as phagosomes (Ackerman et al.,
2003; Cresswell et al., 2005; Inaba and Inaba, 2005). Triage
of antigens between the Class I and Class II pathways then
appears to involve close regulation of the intraphagosomal
pH. The previously acidic pH of the phagosome is ini-
tially increased, favoring antigen processing through the Class
I pathway. After some minutes, these phagosomes are re-
acidiﬁed, permitting antigen processing toward the Class II
pathway (Inaba and Inaba, 2005).
Following triage between MHC class I and class II pathways,
the cross presentation of particulate antigens involves in itself at
least two variant mechanisms. In the Cytosolic Pathway of Antigen
Cross Presentation, antigens are taken up into phagosomes and,
after partial processing in these organelles, exported into the cyto-
plasm where they are hydrolyzed into short peptides within the
proteasome. The processed peptides are then re-imported into
the ER by transporter associated with antigen presentation (TAP),
enter the conventional antigen presentation pathway, and become
loaded onto appropriate MHC class I molecules (Rock and Shen,
2005). A variation on this mechanism has been proposed in which
the antigen processing machinery of the ER becomes associated
with phagosomes and loading onto MHC class I occurs in these
organelles (Rock et al., 2005).
A second, alternative pathway for cross presentation of particu-
late antigens has beendescribed,TheVacuolar Pathway, also known
as the TAP-independent pathway of cross presentation (Rock and
Shen, 2005; Ackerman et al., 2006). This route of antigen presen-
tation is rapid compared to the cytosolic/proteasome pathway and
obviates the need for polypeptides to be pumped in and out of the
cytoplasm. In this case, antigens are taken up into endosomes and
directly processed by endogenous proteases such as the cysteine
protease cathepsin S, loaded onto MHC class I molecules recy-
cling from the cell surface and then trafﬁcked back to the surface
in recycling endosomes.
(b) Soluble antigens appear to be taken up by APC and parti-
tioned toward the MHC class I and MHC class II pathways by
different mechanisms compared to particulate antigens. Sort-
ing to the class I and class II routes occurs at the cell surface
through either non-speciﬁc macropinocytosis or endocyto-
sis, involving surface receptors. Uptake of antigens directed
to the antigen cross presentation pathways may involve Fc
receptors, and c-type lectins including CLEC9A, DC-SIGN,
DEC205, and the mannose receptor 1 (Bonifaz et al., 2002;
Burgdorf et al., 2006, 2010; Idoyaga et al., 2011; Tacken et al.,
2011). C-type lectins have in common the possession of a
recognition domain that determines their carbohydrate speci-
ﬁcity and have been studied mostly in regard to interaction
with pathogens (Geijtenbeek and Gringhuis, 2009). Cross
presentation of internalized antigens next involves the two
variant pathways described above for particulate antigens after
antigen–receptor complexes are internalized into endosomes.
EXTRACELLULAR HSP–PEPTIDE COMPLEXES AND ANTIGEN
CROSS PRESENTATION
The uptake of HSP.PC may involve receptors expressed on the
surface of DC and can precede antigen presentation through the
Class I and Class II pathways (Jeannin et al., 2005; Theriault et al.,
2006; Kurotaki et al., 2007; Murshid et al., 2011b). The receptors
involved in this process appear to differ from those that mediate
uptake of soluble, unchaperoned antigens, and the c-type lectins
involved in the latter process do not seem to be major endocytic
receptors for HSP.PC in APC (Theriault et al., 2006). Instead HSPs
bind mainly to scavenger receptors (SR) such as SRECI/Scarf1,
FEEL-I/Stabilin-1, LOX-1, SRA/CD204, and LRP1/CD91 (Binder
et al., 2000; Delneste et al., 2002; Theriault et al., 2006; Murshid
et al., 2011b; Figure 1). SR were ﬁrst characterized in studies of
uptake of chemically modiﬁed low-density lipoproteins (LDL) by
endothelial cells and appear to bind a wide variety of other mole-
cules, includingHSPs (Murshid et al., 2011b).However,Hsp70 can
be bound by some molecules with c-type lectin speciﬁcity, includ-
ing the natural killer (NK) cell receptor NKG2D; LOX-1 belongs to
both SR and c-type lectin families (Theriault et al., 2006; Murshid
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et al., 2011a).As FEEL-1 is not abundantly expressed inDCwehave
not further pursued its potential role in HSP-mediated antigen
cross presentation (Chu, B., Murshid, A., and Calderwood, S. K.,
unpublished). The status of LRP1/CD91 in HSP binding and cross
presentation is somewhat controversial. This protein has been pro-
posed as a common HSP receptor (Binder et al., 2000; Srivastava,
2002). However, LRP1/CD91 is not abundantly expressed in most
DC subtypes and binding of Grp94, calreticulin, and Hsp70 to the
receptor was not detected in a number of studies (Delneste et al.,
2002; Berwin et al., 2003; Walters and Berwin, 2005; Theriault
et al., 2006). SRA/CD204 plays a signiﬁcant immune suppressive
function after binding HSPs and other ligands and there is cur-
rently no evidence that it plays a role in antigen cross presentation,
although it is capable of mediating internalization of Grp94 and
calreticulin (Berwin et al., 2003; Wang et al., 2007). SRECI and
LOX-1 each appeared to mediate approximately 50% of the cross
presentation of the ovalbumin (Ova) SIINFEKL epitope inmurine
BMDC (Murshid et al., 2010).
It has recently been shown that GRP94 can lead to antigen cross
presentation in a receptor-independent manner, questioning the
signiﬁcance of HSP receptors (Jockheck-Clark et al., 2010). This
issue was also recently examined by Murshid et al. (2010) who
tested the ability of CHO cells to cross prime B3ZT cell hybridoma
cells that respond to Ova peptide SIINFEKL in the context of
H2kb. Wild-type CHO cells or CHO engineered to express H2kb
on the surface and exposed to Hsp90–Ova or Hsp90-associated
with N-terminally extended SIINFEKL failed to cross prime B3Z
cells. However, co-expression of H2kb and the receptor SCRECI
rendered the CHO cells competent to cross prime the B3Z cells
(Murshid et al., 2010). These studies strongly suggest a role for
receptors such as SR in cross presentation of HSP-bound antigens,
although they cannot rule out a role for non-receptor mechanisms
in some cell types (Jockheck-Clark et al., 2010).
The SR were initially shown to be important in HSP binding
andCTL activation using awide range of SR agonists. Compounds
that bind SR such as such as maleylated BSA,Oxidized LDL, acety-
lated BSA, poly-inosine, and fucoidan all reduce Hsp70 binding
to DC (Delneste et al., 2002). Class E SR family member LOX-1
was shown to be expressed at high levels in myeloid derived DC
and in mouse bone marrow derived DC and it was demonstrated
conclusively that this receptor is involved in antigen cross pre-
sentation by DC exposed to Hsp70–antigen complexes (Delneste
et al., 2002). Indeed, anti-LOX-1 antibodies coupled to Ova could
mediate the rejection of Ova expressing tumor cells. Recently, it
was also shown that LOX-1 is an Hsp60 receptor and Hsp60-fused
Ova can be processed by DC and can be delivered to MHCI mol-
ecules to activate CD8+ T cells response, suggesting their role in
antigen cross presentation (Xie et al., 2010).
Class F scavenger receptor SRECI binds avidly toHsp70,Hsp90,
Grp94, Hsp110, and Grp170 with or without associated antigens
and appears to be a common receptor for HSPs in DC (Manjili
et al., 2002; Berwin et al., 2004; Murshid et al., 2010). Hsp90–
antigen complexes can be bound and internalized in a range of cell
types including DC and packaged into distinct classes of vesicles
by SRECI, involving lipid raft localization of the receptor–HSP.PC
complex and taken up in a dynamin- and clathrin-independent
pathway (Murshid et al., 2010). HSP.PC along with SRECI is
endocytosed into tubule like vesicles termedClathrin-independent
carriers (CLIC) orGPI anchored protein-enriched endocytic com-
partments (GEEC; Doherty and McMahon, 2009; Gupta et al.,
2009). Although the signiﬁcance of entry of HSP–SRECI com-
plexes through the CLIC/GEEC pathway is not entirely clear, it
does permit regulation of antigen cross presentation by signal
transducing molecules as discussed below. In addition, LOX-1 is
internalized through a dynamin-dependent mechanism involving
association with caveolae, distinct from the GEEC pathway used
by SRECI but is also able to mediate cross presentation of peptides
bound to HSPs (Murphy et al., 2008).
It is not clear to what degree the antigen presentation pathways
utilized by HSP-chaperoned antigens after endocytosis conform
to those used by unchaperoned antigens. For instance, particu-
late antigen processing toward the class I pathway, involves an
elevation in intraphagosomal pH and it is not yet known if such
processes are important for HSP-mediated antigen processing and
presentation (Inaba and Inaba, 2005). Intravesicular pH changes
could be involved in the dissociation of peptides from the HSP,
as well as subsequent loading onto MHC class I. Cross presen-
tation in BMDC after Hsp90–Ova peptide exposure was reduced
by exposure to chloroquine, an inhibitor of vesicular acidiﬁcation
suggesting that low pH may be required at least for cross presen-
tation through the vesicular pathway (Murshid et al., 2010). So far
it has been established that both the endosome-plasma membrane
and endosome to cytosol-cellmembrane mechanisms are involved in
Hsp70 and Hsp90-mediated antigen cross presentation in BMDC
(Murshid et al., 2010). Partition of antigens between these two
pathways may depend on the size of the client polypeptide associ-
ated with the HSP. Smaller, Ova-derived peptides bound to Hsp90
could be efﬁciently cross presented through a mechanism resem-
bling the vesicular pathway and such processing was blocked by
cysteine protease inhibitors and, primaquine an antagonist of
membrane recycling (Murshid et al., 2010). Larger polypeptides
associated with Hsp90, such as full length ovalbumin required
TAP expression and proteasome function, indicating a key role
for the endosome–cytosol pathway in processing these larger anti-
gens (Murshid et al., 2010). HSP chaperoning of peptide antigens
may increase the efﬁciency of antigen processing by protecting
peptides from proteolysis during trafﬁcking through the cell com-
partments and reducing the amounts of antigen required to initiate
CD8+ T cell cross priming (Kunisawa and Shastri, 2006). One
question that is currently unclear is how far along the journey of
antigen cross presentation the HSP-receptor–polypeptide com-
plex remains intact. Hsp90, SRECI, and Ova-derived peptides
have been detected co-localizing in endosomal compartments of
BMDC (Murshid et al., 2010). In addition, in DC incubated with
Hsp90–Ova complexes, internalized Hsp90 and Ova were shown
to co-localizewith cytosolic proteasomes (Oura et al.,2011). Local-
ization of Ova to proteasomes and TAP-dependent antigen cross
presentation could be abolished by introduction of anti-Hsp90
antibodies into cells, indicating a key role for Hsp90 in targeting
associated Ova molecules to proteasomes (Oura et al., 2011). It
has been shown recently that intracellular Hsp90 plays an essen-
tial role in antigen cross presentation by permitting the transport
of model antigen Ova out of endosomes and into the cytosol
to permit processing by the proteasome (Ichiyanagi et al., 2010;
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Imai et al., 2011). By contrast with free Ova, cross presentation of
Hsp90–chaperoned Ova appeared to be independent of endoge-
nous Hsp90, suggesting that exogenous Hsp90 may facilitate anti-
gen transport across the endosomal membrane independently of
the endogenous chaperone (Oura et al., 2011).Ultimately,peptides
dissociate from the HSP prior to processing and presentation and
receptors such as SREC1 are likely recycled to the cell surface. Flu-
orescently labeled Hsp90 was observed for approximately 60min
in murine BMDC, after binding and internalization, before ﬂuo-
rescence became undetectable (Murshid, A., unpublished data).
Hsp90 taken up from the extracellular medium and entering
endosomes may be broken down by intravesicular proteases or
lysosomal hydrolases.
ROLE OF INTRACELLULAR MOLECULAR CHAPERONES IN
CROSS PRESENTATION OF ANTIGENS IN CELLULAR
MATERIALS ENGULFED BY APC
Tumor cells or virally infected cells may trigger immunity either
directly when MHC class I antigen complexes on the surface inter-
act with CD8+ T cells or when such cells die, are engulfed by
APC and epitopes are cross presented to the CD8+ cells (Wolkers
et al., 2001). There has been some suggestion that HSPs might
play a role in the second process, in cross presentation of antigens
sequestered by molecular chaperones by APC after engulfment of
cell bodies. HSP-chaperoned peptides appear to exist in detectable
quantities in cells and could be signiﬁcant in this latter process.
Indeed it was suggested by Binder et al. (2000) that essentially
all antigenic epitopes in cells may be bound to molecular chap-
erones (Binder and Srivastava, 2005). However in a study of
Ova epitope presentation in cell lysates, free unprocessed proteins
appeared to be the dominant form of antigens for cross priming,
far exceeding the activities of free or HSP-chaperoned peptides
(Shen and Rock, 2004). Most peptides generated by proteolysis
of cytoplasmic proteins have a very short half-life, surviving for
only a few seconds, although a minority can survive for longer
periods by association with TAP (Reits et al., 2003). There has
been some suggestion that HSPs could chaperone such peptides
in the cytoplasm and protect them from cytoplasmic aminopep-
tidases (Srivastava, 2002). Intracellular chaperones may acquire
peptide antigens during endogenous antigen processing (Kuni-
sawa and Shastri, 2003, 2006). Indeed Shastri et al. have shown
that Hsp90a is essential in stabilizing large peptide intermedi-
ates generated by the proteasome from Ova and for presentation
through the MHC class I pathway (Kunisawa and Shastri, 2006).
In addition, a minority of viral epitopes that can bind Hsp90α
appear to be stabilized and are important in cross priming (Lev
et al., 2008). However the exact place of HSPs in cytoplasmic
antigen processing is uncertain. When peptides are taken up by
TAP into the ER they could potentially encounter other mole-
cular chaperones, including the Hsp70 paralog Grp78 and the
Hsp90 paralog Grp94, molecules with suspected immune func-
tions. It is not clear whether Grp78 binds peptides or participates
in antigen presentation although it has known immune func-
tions in the chaperoning of IgG (Kozutsumi et al., 1989). In
addition, Grp94 does not appear to participate in cross prim-
ing of anti-viral CD8+ cells in vivo (Nicchitta, 2003; Lev et al.,
2009). Another ER chaperone shown in vitro to bind avidly to
polypeptide clients is Grp170 (Park et al., 2006). However it is not
clear whether ER resident Grp170 can acquire peptide antigens
in vivo or can play a role in antigen presentation, although its high
avidity for peptides and proteins suggests investigation of such a
possibility.
RELEASE OF HSPs FROM CELLS INTO THE EXTRACELLULAR
ENVIRONMENT
Heat shock proteins can also be released from cells, tissues, and
access the extracellular environment, although their functions out-
side the cell are largely unknown and much debated (Pockley et al.,
2008). HSPs can be released from tumor cells or macrophages into
the extracellular microenvironment through mechanisms involv-
ing secretory lysosomes, very similar to the processes used by
cells to release interleukin-1β (Mambula and Calderwood, 2006b).
This pathway of non-canonical HSP secretion occurs at a grad-
ual basal rate and can be triggered in cells by stresses such as
fever range heat or by exposing macrophages to live E. coli bacte-
ria (Mambula and Calderwood, 2006b; Mambula, S. S., Murshid,
A., and Calderwood, S. K., in preparation). HSPs released in this
way could potentially export antigenic peptides acquired during
intracellular antigen processing as cargo, interact with APC and
trigger cross priming of CD8+ subsets. However, it is not clear
how stable antigen binding would be under these circumstances.
It is known that for hspa family chaperones such as Hsp70, pep-
tide binding is relatively stable when ADP rather than ATP is
bound to the chaperone. Hsp70 is also released from necrotic
cells and under these circumstances might be thought to bind
associated polypeptides, as intracellular ATP levels would decline
rapidly in necrosis and the chaperone, in its ADP-bound form
would bind peptides more effectively (Mambula and Calderwood,
2006a). Hsp70 released from cells undergoing necrotic death
has been shown to lead to a strong T cell mediated anti-tumor
immune response (Daniels et al., 2004). In addition, it was shown
that Grp170, engineered for secretion into the extracellular envi-
ronment initiated tumor rejection due to activation of NK and
CD8+ cells, indicating the potential of this approach (Wang et al.,
2003).
In addition to secretion in free form, HSPs have been shown to
be released from cells after being packaged in exosomes. Exosomes
derived from multivesicular bodies in DC contain Hsp70 and are
known to play a major role in cross priming of T lymphocytes
(Chaput et al., 2006). Thus Hsp70 in exosomes could poten-
tially play a signiﬁcant role in immunity. However, exosomes from
tumors (EL4 Thymoma) which contain Hsp70 on the vesicular
surface were shown to be immunosuppressive through interac-
tion with myeloid derived suppressor cells (MDSC; Chalmin et al.,
2010). Relatively little work has been carried out in this interesting
area and we anticipate further studies.
EXTRACELLULAR HSPs AND THE CLASS II PATHWAY
Cross presentation of HSP-associated antigens, although essential
would not be sufﬁcient to fully program CTL and in the absence
of other signals, CTL would ultimately fail to actively prolifer-
ate and could undergo programmed cell death. For a sturdy CTL
response, DC would process and present antigens via the MHC
class II pathway and thus activate CD4+ T helper cells. It has
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been shown that HSPs can chaperone external antigens through
the MHC class II pathway and activate CD4+ T cells (Gong et al.,
2009). As mentioned above, unchaperoned antigens, after uptake
into phagosomes, traverse separate trafﬁcking routes in DC that
direct them to compartments in which association with MHC
class I or II molecules can occur. It is not clear which mechanisms
are involved in the partitioning of HSP-chaperoned antigens into
these pathways. We have shown however that SRECI is involved in
HSP-mediated CD4+ T cell activation and our preliminary stud-
ies indicate that the early endocytic and regulatory stages of this
process, such as uptake of HSP.PC through SRECI, involve sim-
ilar pathways to those in Class I presentation (Gong et al., 2009;
Murshid, A., and Calderwood, S. K., in preparation). Activation
of CTL is thought to require DC licensing, in which an individ-
ual DC interacts with both CD4+ and CD8+ T cells (Bennett
et al., 1997, 1998). Initial interaction of CD40 ligand on the CD4+
T cell surface with CD40 on the DC sets in motion a series of
events including the induction of co-stimulatory molecules such
as CD80 (B7-1), CD86 (B7-2) that permit subsequent CD8+ T
cells activity (Kurts et al., 2010; Figure 1). Co-stimulatory mole-
cules are recognized by counter receptors such as CD28 expressed
on T cells and reinforce the signals induced in CD8+ T cells by
MHCI–peptide complex-T cell receptor binding (van der Merwe
et al., 1997; Rudd et al., 2009; Figure 1). Most HSPs are likely to
bind to a wide spectrum of intracellular antigens, containing both
MHC class I and class II epitopes and may favor the reactions
involved in DC licensing.
HSP ASSOCIATION WITH PATTERN RECOGNITION
RECEPTORS
Cytotoxic lymphocytes activation can also be reinforced by sig-
nals induced by pathogen-associated molecular patterns (PAMPs).
During infection, PAMPs bind to several classes of pattern recog-
nition receptors (PRR) such as such as Toll-like receptors (TLR)
and trigger innate immune responses in APC (Yamamoto and
Takeda, 2010). This type of signaling activates a number of tran-
scription factors, most notably nuclear factor-κB (NFκB) that can
stimulate transcription of genes encoding inﬂammatory cytokines
and co-stimulatory molecules such as B7-1 and B7-2 (Parra et al.,
1995; Rudd et al., 2009). Innate immune activation through these
pathways can thus reinforce CTL programming through pathways
overlapping those induced by CD40L–CD40 interactions between
CD4+ T cells and DC (Maurer et al., 2002; Schulz et al., 2005;
Najar and Dutz, 2007; Figure 1). HSPs may potentially function
as DAMPs (damage associated molecular patterns) and induce
innate immunity under sterile conditions through interactionwith
PRR (Chase et al., 2007; Wheeler et al., 2009). Indeed, there is
an evidence for HSPs interacting with PRR such as TLR2 and
TLR4 (Gong et al., 2009; Figure 1). It was shown that SRECI-
dependent tumor immunity induced by Hsp70 vaccines requires
TLR signaling and knockout of the TLR signaling intermediate
Myd88 or the receptors TLR2 and TLR4 obliterates tumor immu-
nity (Gong et al., 2009). In addition to affecting innate immune
transcription, TLR signaling also mediates a number of stages in
antigen cross presentation and positive HSP interaction with TLRs
may thus reinforce antigen cross presentation (Amigorena and
Savina, 2010). As CTL programming involves the interaction of
three rare cell types, including DC, CD8+ T cells, and CD4+ T
cells, this conﬂuence may be strongly inﬂuenced by the release of
inﬂammatory CCL cytokines from DC. It may be notable that
Hsp70 has been shown to trigger release of CCL cytokines in
a TLR4 dependent manner and that mycobacterial Hsp70 binds
directly to CCL receptor CCR5 (Whittall et al., 2006; Chen et al.,
2009).
HSP–SCAVENGER RECEPTOR INTERACTIONS AND
TRANSMEMBRANE SIGNALING
In addition to internalizing bound peptides, ligand-bound HSPs
may play signiﬁcant roles in cell signaling pathways that impact
immunity. LOX-1 and SRECI can both interact with TLR2 to
induce innate immune signaling and transcription (Jeannin et al.,
2005). Although little is known regarding HSP–LOX-1 signal-
ing, binding of LOX-1 to other ligands, such as modiﬁed LDL
induces MAP kinase activity, NF-κB, and pro-inﬂammatory sig-
naling through the small intracellular domain of the receptor
(Chen et al., 2002). However, when HSPs interact with class I
scavenger receptor SRA/CD204, innate immune signaling through
TLR4,NFκB, and MAP kinase is reduced, and CD4+ T cell activa-
tion is inhibited (Yi et al., 2011).Knockout of the SRA/CD204 gene,
although decreasing Hsp110 binding to DC led to a profoundly
increased ability to stimulate melanoma antigen gp100-speciﬁc
naïve T cells, compared towild-typemice (Qian et al., 2011). HSP–
SR interactions may thus send both pro-immune and inhibitory
signals resulting in a tightly regulated system. Signaling through
SRECI appears to reinforce antigen cross presentation and the
appearance of SRECI in lipid rafts after binding Hsp90 may be
a key stage in this process (Murshid et al., 2010). Lipid rafts are
cholesterol- and sphingolipid-rich membrane microdomains that
can concentrate molecules involved in cell signaling (Lingwood
et al., 2009).Although lacking the glycerophosphoinositide anchor
domain motifs found in many raft-associated membrane proteins,
SRECI contains other motifs that would permit it to associate with
lipid rafts (Murshid et al., 2011a). Indeed, Hsp90–SRECI com-
plexes associate with the small GTPase Cdc42 and non-receptor
tyrosine kinase Src, molecules tightly associated with lipid rafts
(Murshid et al., 2010). These associations appear to be impor-
tant in regulating antigen cross presentation of Hsp90-associated
antigens in DC.
Lipid rafts also concentrate intermediates in the TLR4 signal-
ing pathway in response to innate immune stimuli (Triantaﬁlou
et al., 2002). Indeed, preliminary studies show signiﬁcant co-
localization of Hsp90–SRECI complexes with TLR4 (Murshid,
A., and Calderwood, S. K., in preparation). HSP-triggered sig-
naling through SRECI and LOX-1 may thus be involved both in
amplifying antigen cross presentation and in stimulating innate
immunity and these receptors may operate in concert to thwart
the inhibitory effects of HSP–SRA/CD204 signaling. It may be
signiﬁcant that LOX-1, with essentially no sequence similarity to
SRECI associates with TLR2 after ligand binding and mediates
immune responses in a similar way to SRECI (Jeannin et al., 2005).
The similarity in immune properties and protein interaction
partners between SRECI and LOX-1 despite sequence homology
may suggest functional interaction on the cell surface after HSP
binding.
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CONCLUSION
On theoretical grounds, HSPs might be seen as ideal sources
of tumor antigens due to their high abundance in cancer and
their molecular chaperone functions. However, the nature of the
polypeptides chaperoned byHSPswhich carry the“antigenic load”
of the HSP.PC is less clear. Most cytoplasmic peptides appear to
be in free, unchaperoned form unless acquired by TAP, although
Hsp90 appears to be an exception to this rule and appears to
be capable of binding to peptides exiting the proteasome. How-
ever, Hsp70 and Hsp90 both associate with intact proteins in vivo
during protein folding and quality control, and the antigenic
nature of extracellular HSPs extracted from tumors may thus
at least partially reﬂect stable chaperone binding to antigenic
proteins.
It seems clear that HSPs can mediate cross presentation of
acquired tumor antigens by APC. This process may involve
receptor-mediated uptake by SR LOX-1 or SRECI or receptor-
independent uptake. If small peptides are bound to HSPs they
can then be presented to CD8+ cells through the rapid vacuolar
pathway of antigen cross presentation. Hsp90 appears to be able
to chaperone whole proteins such as ovalbumin across the plasma
membrane, into endosomes, and direct them to the proteasome
for processing and presentation by MHC class I molecules.
In addition to directing antigens toward the Class I pathway,
HSPs can chaperone antigens toward the Class II pathway of
antigen presentation. This effect may be signiﬁcant in recruiting
antigen-speciﬁc Th1 helper cells to mediate DC licensing and
amplify CTL processing.
Association of HSP–antigen complexes with SR SRECI and
LOX-1 may help to amplify cross presentation of antigens by trig-
gering signal transduction pathways emanating from lipid rafts.
HSP-bound SR can associate with lipid rafts and activate sig-
naling through small GTPase Cdc42, tyrosine kinase c-sec, and
induce activity of PRR such as TLR2. There also appear to be
HSP-mediated regulatory signals and binding to SRA/CD204 can
inhibit immunity.
There remains a need to identify a number of unresolved cell
biological and biochemical aspects of HSP.PC-mediated immu-
nity. These include further investigation of the signals initiated
when HSPs bind to cell surface receptors, the kinetics of com-
partmentalization of the chaperoned peptides and the routes of
trafﬁcking and processing of peptides after release from HSP.
Advanced technology studies of the trafﬁcking of single cell mol-
ecules may open up this ﬁeld. Elucidating the mechanisms of
antigen cross presentation of HSP-bound antigens via MHCI
and the signaling events associated with this immunogenic effect
may allow development of superior HSP-based vaccines and
immunotherapy protocols.
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